TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: preservation of torsional stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects achieving rSBA titers ≥1:8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adverse events at 1 month postbooster
Endpoint domain: Adverse events/effects
Primary endpoint: ITSEA Dysregulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Annual per-patient costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: leg and back muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of population reaching TC <15 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average transport time (TT) to TC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive response to bupropion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prefrontal concentrations of N-acetylaspartate (NAA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: FRS score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Deficits in neurocognitive functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immediate patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Leakage from the anastomotic site
Endpoint domain: Adverse events/effects
Primary endpoint: Time to achieve full enteral nutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily vegetable intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily fruit intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major bleeding risk
Endpoint domain: Mortality/survival
Primary endpoint: Myocardial infarction (MI) risk
Endpoint domain: Mortality/survival
Primary endpoint: gains in appendicular lean mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in SPPB score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower risk of rheumatoid arthritis (RA)
Endpoint domain: Mortality/survival
Primary endpoint: Reduced hair shedding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Increased total hair count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in scalp biomarker values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Phlebitis occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in skin health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: muscular strength improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: postural balance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: thickening of the central fovea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ROM of the neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: skin-to-bone distance (SBD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: resumed regular amount of oral intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BAL levels of M30
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recession coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day cardiovascular composite endpoint
Endpoint domain: Mortality/survival
Primary endpoint: 30-day days alive out of hospital (DAOH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in acute care utilization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Energy expenditure (AT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: disappearance rate of dizziness and chest distress on day 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of unmet needs
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: mfERG RADs improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response time improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Accuracy in Go/No-Go Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Berg-Wisconsin Card Sorting Correct Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of proinsulin-specific T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Inhibition of T-cell immunosenescence-like changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: balance self-efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative IIEF-5 scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: respiratory symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cue-induced hypoalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cue-induced hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: thoracic configuration changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Detection rates for upper GI lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sensitivity of LCI for detection of upper GI lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Specificity of LCI for detection of upper GI lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: cardiovascular/respiratory autonomic functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 30-day overall hospital readmission rates
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: 365-day overall hospital readmission rates
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Nasal septal deviation angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall rates of correct diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consumption of remifentanil and sufentanil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parental satisfaction scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: TUG-measured time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lumbar flexor and extensor muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: MBI emotional exhaustion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: life satisfaction levels
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of children drinking tap water on school mornings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stiffness and hardness of the NiTi alloy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: corrosion of the NiTi alloy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CNS progression-free survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: CNS objective response rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CNS depth of response (DepOR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean intersection over union for full-tooth segmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average median surface deviation from SA segmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean total time for segmentation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: cumulative isotretinoin dosage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: adverse events (flare and dryness)
Endpoint domain: Adverse events/effects
Primary endpoint: Glycometabolic Control Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Response Rate (≥CR rate)
Endpoint domain: Mortality/survival
Primary endpoint: Geometric mean faecal egg counts reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Tablet acceptance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall Survival (OS) at 3 years
Endpoint domain: Mortality/survival
Primary endpoint: time before symptom alleviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: leisure time physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-month PSA ≤ 0.2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: > 2 years PFS
Endpoint domain: Mortality/survival
Primary endpoint: neonatal resuscitation knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: learning motivation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Renal pelvic pressure (RPP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Postoperative complications (modified Clavien grade)
Endpoint domain: Adverse events/effects
Primary endpoint: Concerns about medication safety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concerns related to social needs
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Pain documented as present
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Less roughness in voices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Less vocal fry in voices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of perforator visualization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of ICGA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive predictive value of ICGA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical function and balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safe falling techniques
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived barriers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: morphine equivalent daily dosage of opioids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracerebral hemorrhage (ICH) rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Unfavorable outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: SARS-CoV-2 load in the oropharynx
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of comorbid diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PAC-QOL scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Amount of postpartum hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of various stages of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sense of delivery control
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decrease in alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in anxiety and depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increase in subjective happiness scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: clinical pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stability of miniscrews
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammation of the oral mucosa
Endpoint domain: Adverse events/effects
Primary endpoint: Pain lasting longer than 48 hours after implantation
Endpoint domain: Adverse events/effects
Primary endpoint: Mean defect (MD) of visual field decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean sensitivity (MS) of visual field increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG power spectral density (PSD) in low alpha at AF3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ELF score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Rates of urine culturing per 1000 resident days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rates of urinary antibiotic prescriptions per 1000 resident days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: improved intestinal perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dice similarity coefficient values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Jaccard distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average ADR (Adverse Detection Rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sFlt‐1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total drainage volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: delay time in the VLA muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: early rate of force development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: V˙ O2peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean systolic BP differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: intracranial haemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: intense subjective responses (blunting feelings of being 'drunk' and 'impaired')
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of a positive OF test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of maternal anemia at delivery (hgb < 11 g/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of maternal hgb < 10 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuation of LNG-IUS treatment
Endpoint domain: Adverse events/effects
Primary endpoint: mRS score of 0 to 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kinesiophobia levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in cerebral blood flow velocity (MCAVmean)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decline in HbA1c levels from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Complete degradation of stents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Correlation between PPV and icIVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Correlation between PPV and idIVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mRNA expression of NLRP3 inflammasome components
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: plasma levels of IL-1β and IL-18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ability to quit or reduce drinking to nonhazardous levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge about negative effects of hazardous drinking on HIV disease progression
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Positive staff interactions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: momentary elevations in BD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: momentary reductions in BD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Cmax for 15 mg in FSHD subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean AUC0–12 for 15 mg in FSHD subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-dependent concentrations in muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive decline (ECog score ≥2)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: comprehensive cure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Association of cigarette smoking with AAV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AR-C124910XX plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: peri-implant osteogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall RoB assessment accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in average number of headache days of at least moderate severity per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with a ≥50% reduction in average number of headache days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in injurious falls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neuropathy events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total lung volume measurement bias
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung density measurement reproducibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in general health (GHQ-28)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Detection rate of SGA infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Specificity of ultrasound methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Area under the ROC curve for SGA prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Systolic arterial BP decrease >30%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MAP decrease >30%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MOAA/S score ≤3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: facial skin blood flow reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: duration of flushing reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: facial edema reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of circulating lymphocyte numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Engraftment outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Anxiety levels (STAI-T and STAI-D scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores (VAS scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: impact of PIFU on overall survival
Endpoint domain: Mortality/survival
Primary endpoint: LH prevalence and size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of decrease of HYPOs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Costs of health interventions for HYPOs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: hospital admission
Endpoint domain: Mortality/survival
Primary endpoint: Graft success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Graft neovascularisation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft epithelisation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete clinical regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes